{"id":"W4286296240","doi":"10.1200/jco.2022.40.16_suppl.2505","title":"Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Pharmacokinetics; Internal medicine; Pharmacology; Oncology; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001577801,0.002475326,0.002122595,0.0005657994,0.0005642112,0.001079102,0.00110072,0.001206121,0.004626546],"category_scores_gemma":[0.0007012673,0.001036333,0.001255056,0.0003838476,0.001091846,0.0008408456,0.0004060853,0.003765961,0.00134085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001624528,"about_ca_system_score_gemma":0.002377624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00142348,"about_ca_topic_score_gemma":0.003015764,"domain_scores_codex":[0.9995004,0.0001956436,0.00002014252,0.00008028805,0.00006704275,0.0001364617],"domain_scores_gemma":[0.9994565,0.00005824142,0.000110804,0.00005336415,0.00004599808,0.0002751383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.49606,0.2896541,0.00481836,0.0007955907,0.001610322,0.0003503034,0.0004855898,0.004416346,0.1253885,0.0004214989,0.008540132,0.06745928],"study_design_scores_gemma":[0.3338612,0.6352623,0.01090574,0.00002905658,0.0005318706,0.0003142821,0.00007430481,0.001971431,0.01206341,0.0002741712,0.004663741,0.00004856632],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884952,0.001353651,0.001077125,0.0003199497,0.0001355979,0.005087909,0.001836688,0.0001648753,0.001529059],"genre_scores_gemma":[0.9794371,0.001621599,0.003424903,0.0008252686,0.0001736944,0.005701197,0.003349524,0.00007246254,0.005394227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004626546,"threshold_uncertainty_score":0.0154773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05910397734427379,"score_gpt":0.457865669327313,"score_spread":0.3987616919830392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}